TITLE: The effect of balanced energy-protein supplementation provided to lactating women on maternal and infant outcomes: study protocol for a prospectively planned individual patient data (IPD) meta-analysis

AUTHORS: Mihaela A. Ciulei,¹ Shouhao Zhou,² Kelly Gallagher,^{1,3} Sunita Taneja,⁴ Nita Bhandari,⁴ Patrick Kolsteren,⁵ Ameer Muhammad,⁶ James M Tielsch,⁷ Alemayehu Argaw,⁵ Ranadip Chowdhury,⁴ Parul Christian,⁸ Trenton Dailey-Chwalibóg,⁵ Brenda de Kok,⁵ Daniel J. Erchick,⁸ Fyezah Jehan,⁹ Joanne Katz,⁸ Subarna Khatry,¹⁰ Carl Lachat,⁵ Tsering P Lama,¹⁰ Muhammad Imran Nisar,⁹ Yasir Shafiq,⁹ Ravi Upadhyay,⁴ Alison D Gernand,^{1*} Maternal BEP Studies Harmonization Initiative

AFFILIATION:

¹Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA

²Department of Public Health Sciences, Division of Biostatistics and Bioinformatics, The Pennsylvania State College of Medicine, Hershey, PA, USA

³Ross and Carol Nese College of Nursing, The Pennsylvania State University, University Park, PA, USA

⁴Centre for Health Research and Development Society for Applied Studies, New Delhi, India ⁵Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium

⁶VITAL Pakistan Trust, Karachi, Pakistan

⁷Department of Global Health, The George Washington University Milken Institute School of Public Health, Washington D.C., USA

⁸Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

⁹Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan ¹⁰Nepal Nutrition Intervention Project-Sarlahi, Lalitpur, Nepal

***Corresponding Author:** Alison D. Gernand, 110 C Chandlee Lab, The Pennsylvania State University, University Park, PA 16802 adg14@psu.edu

Tables: 3

Word count: 3683/4000

1 Abstract (315/350)

- 2 Background:
- 3 The high prevalence of infant stunting and maternal undernutrition in low- and middle-income
- 4 countries poses a significant public health threat. The World Health Organization recommends
- 5 balanced energy-protein (BEP) supplementation to pregnant women from populations with a
- 6 high prevalence of underweight (prepregnancy $BMI < 18.5 \text{ kg/m}^2$), leaving a notable gap in
- 7 guidance for lactating women. To address this problem, we established the Maternal BEP
- 8 Studies Harmonization Initiative (BEP Initiative) to investigate the impact of BEP
- 9 supplementation given to pregnant and/or lactating women on maternal and infant outcomes by
- 10 synthesizing data from multiple clinical trials. This is a study protocol for our prospective
- 11 individual participant data (IPD) meta-analysis on BEP lactation trials.

12 Methods:

- 13 Data from four randomized controlled trials that include mother-infant dyads in India (n=816),
- 14 Pakistan (n=957), Burkina Faso (n=800), and Nepal (n=726) will be pooled and analyzed.
- 15 Women were randomized to BEP (one trial had a third arm with maternal BEP plus infants
- 16 receiving azithromycin) or control groups at baseline (during the first week) and received the
- 17 intervention through six months postpartum. A one-stage IPD meta-analysis will be done using
- 18 mixed-effects linear and log-binomial regression models to account for between-trial
- 19 heterogeneity. The primary outcome of infant length-for-age z scores (LAZ) at six months of age
- 20 and secondary outcomes of maternal and infant indicators of nutritional status at six months of
- 21 age will be examined. Also, we will examine baseline characteristics as covariates and effect
- 22 modifiers for the BEP to outcome relationship. Risk of bias assessments will be carried out for
- 23 each of the individual trials using the Cochrane risk of bias tool.

24 **Discussion:**

- 25 This prospective IPD meta-analysis uses a one-stage IPD meta-analysis, which allows for higher
- statistical power to examine outcomes, more flexibility in defining variables, and has the ability
- to examine many individual- and study-level variables as effect modifiers, allowing conclusions
- on which individuals or populations may benefit more from BEP given during lactation.
- 29
- 30 Trial registration: This protocol was pre-registered in Open Science Framework
- 31 (<u>https://osf.io/9nq7z</u>)
- 32 Keywords: IPD meta-analysis, BEP supplementation, balanced energy-protein supplementation,
- 33 lactation, women, low- and middle-income countries, LMIC

34 BACKGROUND

- 35 Pregnant and lactating women with undernutrition are at high risk of adverse maternal and infant
- health outcomes. Often, undernutrition is characterized by low body mass index (BMI), low mid-
- 37 upper arm circumference (MUAC), short stature, and/or micronutrient deficiencies, which put
- 38 pregnant women at risk for complications such as intrauterine growth restriction and preterm
- birth (1). The World Health Organization (WHO) recommends balanced energy-protein (BEP)
- 40 supplementation in populations at risk of underweight (defined as more than 20% of pregnant
- 41 women with a BMI $< 18.5 \text{ kg/m}^2$) to reduce the risk of stillbirth and small for gestational age
- 42 neonates (2). However, the consequences of undernutrition among lactating women have
- 43 commonly been overlooked. Lactating women require additional calories to produce milk, and
- 44 maternal weight status may impact the volume of milk produced and available for infant
- 45 consumption (3). In food insecure settings, particularly in low- and middle-income settings, there
- is a high prevalence of infant stunting (4–6). Stunting, or impaired growth due to inadequate
- 47 nutrition, can have serious long-term consequences for children's health and development.
- 48 Meanwhile, breast milk is often the sole or main source of calories and nutrients for infants
- 49 under six months of age in low-resource settings, and supplementing the diet of women who are
- 50 breastfeeding could have a direct impact on infant growth and health.
- 51
- 52 BEP supplementation products are ready-to-use or prepared foods that provide energy and
- protein (accounting for less or equal to 25% of the total energy content) (7). When given during
- 54 pregnancy, packaged BEP products are often fortified with multiple micronutrients or if BEP is
- in the form of locally-prepared food, it is often given along with a multiple micronutrient or iron
- and folic acid (IFA) tablet. The current evidence in systematic reviews and meta-analyses has
- 57 focused on studies where BEP supplements are given during pregnancy, and synthesis is lacking
- for trials giving BEP during lactation (8-12).
- 59
- 60 To align BEP product formulations, the Bill & Melinda Gates Foundation (BMGF) assembled an
- expert panel in 2017 to develop guidelines for the macro- and micronutrient content of BEP
- 62 supplements for pregnancy and lactation (7). The panel also recommended that BEP products be
- 63 developed and evaluated in both pregnant and lactating women in low-resource settings to assess
- health benefits. To further advance the evidence-based research, BMGF funded several
- 65 independent RCTs and in 2020, convened the Maternal Nutrition Harmonization Workshop to
- 66 harmonize key variables across these trials and prioritize outcomes for the IPD meta-analysis
- 67 (13). This later led to the formation of the Maternal BEP Studies Harmonization Initiative
- 68 (hereinafter BEP Initiative) to examine the pooled effect of BEP in pregnancy and lactation on
- 69 maternal and child health.
- 70
- 71 The current protocol describes the objectives, data, and analysis plan of our prospective
- 72 individual participant data (IPD) meta-analysis that focuses on the effect of BEP
- raise supplementation given during lactation in four trials with similar designs, outcome measures, and
- settings (i.e., low-and middle-income countries (LMIC)). The primary aim of this IPD meta-
- analysis is to assess the effect of BEP supplementation in lactating women on infant length-for-
- age z scores (LAZ) at six months of age. For secondary outcomes, we will assess maternal and
- infant weight and malnutrition indicators at six months postpartum. Last, we will examine
- maternal and infant characteristics that may modify the relationship between BEP intervention
- 79 and outcomes.

80 METHODS/DESIGN

81 **Protocol and registration**

- 82 This protocol was preregistered in Open Science Framework (<u>https://osf.io/9nq7z</u>) and all
- individual trials were prospectively registered online (**Table 1**). We followed The Preferred
- 84 Reporting Items for Systematic Reviews and Meta-Analysis-Protocol framework, and the
- checklist is appended.(14) The reporting of the IPD meta-analysis will use the PRISMA-IPD
- reporting checklist (15).

87 Trials and sample size

- 88 Four BEP supplementation trials during lactation will be included in this prospective IPD meta-
- analysis located in: India (IMPRINT), Burkina Faso (MISAME-III), Pakistan (MumtaLW), and
- 90 Nepal (MINT) (see **Table 1** for study information and acronym definitions). All four studies are
- 91 part of the BEP Initiative. Recruitment is complete for IMPRINT, MumtaLW, and MISAME-III,
- 92 and sample sizes are as follows: IMPRINT (n=816), MumtaLW (n=957), MISAME-III (n=800),
- and MINT (n=726). The expected total sample size is 3,299 women. The sample size for some
- 94 exploratory outcomes will be lower than the total enrollment sample size due to certain
- 95 information (e.g., blood collection or analysis) being collected on a subset of participants (by
- design). Also, the sample size for the MISAME-III and MINT trials is lower than the sample size
- 97 for the full trials because these trials have a factorial design to provide BEP during pregnancy
- and/or lactation. Groups receiving BEP supplementation during pregnancy are not included in
- this analysis. Risk of bias assessments will be carried out and reported for each of the individual
- trials using the Cochrane risk of bias tool (16). There is no risk of duplicate data.

101 **Power calculations**

- 102 For this prospective meta-analysis, we assume the mean LAZ at six months of age to be -0.57
- 103 (standard deviation 1.10) in the control group(17). A total sample size of 3,299 (1,809 for BEP
- package group and 1,490 for control group) yields 88% power to detect a minimum LAZ
- difference of 0.10 between BEP and control at a significance level of 5% using mixed-effects
- 106 linear regression, and assuming an intra-class correlation as low as 0.30. For secondary
- 107 outcomes, we will have 89% power to detect a standardized mean difference of 0.10, assuming
- an intra-class correlation as low as 0.20. The PASS Software v22.0.4 was used for sample size
- 109 calculation (NCSS, LLC, Kaysville, Utah).

110 Participants, eligibility, and study design

- 111 In the IMPRINT trial, mother-infant dyads were included in the study if a participant initiated
- breastfeeding within seven days postpartum. In the MumtaLW trial, lactating women with
- undernutrition (MUAC <23.0 cm), between 13-49 years of age, and their newborns (captured
- 114 within seven days from birth) were included in the study. Additionally, lactating women had to
- intend to exclusively breastfeed the infant for the first six months of age. In the MISAME-III and
- 116 MINT trials, women between 15-40 and 15-30 years, respectively, were enrolled in the study
- 117 following a positive urine test if they were found to be missing menstruation in the prior five
- 118 weeks and following an ultrasound examination that revealed an intrauterine pregnancy <21
- 119 completed weeks of gestation. They were in the trial from early gestation through 6 months
- postpartum and were counseled to exclusively breastfeed for 6 months. Additionally, in all trials,
- 121 participants indicated that they were not allergic to BEP ingredients (e.g., peanuts).
- 122

- **Table 1** summarizes the basic study information for included maternal BEP lactation trials.
- 124 Among them, IMPRINT followed an individual randomization, controlled efficacy trial design.
- 125 MumtaLW followed a multi-arm, community-based randomized controlled, open-label, assessor-
- blinded superiority trial design with a treatment allocation ratio of 1:1:1. MISAME-III was an
- 127 individual randomized 2x2 factorial efficacy design where participants are individually and
- 128 randomly allocated to a prenatal intervention or control and a postnatal intervention or control
- group. Similarly, MINT followed a household randomized 2x2 factorial efficacy design where
- participants in the same household obtained the same prenatal and postnatal intervention or
- 131 control. The current analyses will focus only on the postpartum intervention.

132 Intervention

- 133 The intervention tested in each trial was a BEP supplement given to women from birth (or within
- a week of birth) to six months postpartum. The intervention groups also received what the
- 135 control group received as the standard of care (see below) in addition to BEP. IMPRINT's
- 136 nutritional intervention was five different BEP snacks produced by a local company and a
- 137 separate multiple micronutrient supplement (**Table 2**) (18). The MumtaLW trial provided a BEP
- local product called Mumta that is fortified with multiple micronutrients; two sachets per day
- 139 were provided (19). MumtaLW had a third intervention arm in which the women received BEP
- and the infants also received one dose of azithromycin at 42 days. The MISAME-III and MINT
- trials provided a micronutrient fortified BEP supplement produced by the Nutriset (Malaunay,
- 142 France) (20).

143 Control/Standard of care

- 144 All four trials had a control arm that was intended to align with the standard of care for
- 145 postpartum women in each country (Table 2). In the IMPRINT trial, women were encouraged to
- 146 use IFA, calcium, and vitamin D supplements for six months postpartum from the national
- 147 program in India (i.e., not provided by the trial) (18). The national program also provides a food
- supplement that contains 600 kcals (18-20 g protein). In the MumtaLW trial, women received
- 149 IFA from the government program or the trial (i.e., the trial ensured it was provided) for six
- 150 weeks postpartum. In the MISAME-III trial, women also received IFA from the trial for six
- 151 weeks postpartum. Finally, in the MINT trial, IFA was not provided as it was not part of the
- standard of care during lactation in Nepal.
- 153
- 154 Most trials provided participants (intervention and control) with counseling for nutrition,
- breastfeeding, and infant care, or referred to services where counseling was available. Trials also
- encouraged women to use postnatal clinical care for themselves and their infants and referred to
- 157 clinical services in the case of illness.

158 **Outcomes and prioritization**

- 159 The primary outcome for this IPD meta-analysis is infant length-for-age z score (LAZ) at six
- 160 months of age, which represents linear growth across that timeframe. Secondary outcomes
- 161 include infant weight and malnutrition at six months of age (weight-for-length z score (WLZ)
- and weight-for-age z score (WAZ)), infant growth velocity (i.e., change in length and weight),
- infant stunting (LAZ <-2), wasting (WLZ <-2), and underweight (WAZ <-2)) at six months of
- age. All infant weight and nutrition status indices (LAZ, WAZ, WLZ) will be calculated based
- on WHO Growth Standards (21) (or INTERGROWTH-21st for infants born preterm, when
- 166 gestational age is available), which are sex-specific. We will also assess maternal anthropometry

- including mean BMI and MUAC, underweight (BMI <18.5 kg/m²) and low MUAC (<23.0 cm)
- 168 at six months postpartum (**Table 3**).
- 169
- 170 Exploratory outcomes include infant head circumference-for-age and MUAC-for-age z scores
- 171 (based on WHO Growth Standards, see above) at six months; maternal and infant biomarkers for
- iron deficiency, anemia, inflammation, and other micronutrients at six months of infant age
- 173 (ferritin, transferrin receptor, hemoglobin, C-reactive protein (CRP), alpha-1-acid glycoprotein
- 174 (AGP), other micronutrients (biomarkers to be determined)); and maternal mortality rate (per
- 175 100,000 live births) and infant mortality rate (per 1,000 live births; Table 3).

176 Individual- and study-level covariates

- 177 Individual-level variables collected by trials for women include maternal age, education, baseline
- 178 weight and height, parity, adherence to BEP, health and pregnancy history, diet, breastfeeding
- type (exclusive, predominant, and partial), and household food insecurity. For infants, variables
- include sex, gestational age at birth, age at each measurement (calculated from birth date),
- 181 weight, length, head circumference, and MUAC. Nutritional biomarkers are available for some
- 182 maternal and infant blood samples (see list in exploratory outcomes). Study-level variables
- include nutritional content of BEP, geographic setting (Africa or South-East Asia), and
- 184 prevalence of undernutrition in study population (e.g., infant stunting or maternal underweight).

185 IPD data collection and flow

- 186 Data for this meta-analysis will come from the four participating trials. The investigators of each
- trial have agreed to provide data and will send individual trial datasets to a data repository
- 188 (hosted by the study sponsor). Trial investigators will remove personal identifiers, and the data
- repository analysts will further scan for and remove any identifiable information. Then, de-
- 190 identified data will be shared with the meta-analysis research team at Penn State. After Penn
- 191 State receives individual data sets, they will clean and merge them to create a pooled dataset for
- the IPD meta-analysis. While working with these data sets, only the Penn State IPD meta-
- analysis research team will have access to the individual and pooled datasets, which will be
- 194 stored in a secure drive, password protected by the university.

195 Data merging and quality assurance (IPD integrity)

- 196 Each trial will share their original data to the data repository team, which will prepare de-
- 197 identified datasets. First, we will review the dataset processed by the data repository team to see
- 198 if it includes all variables needed for the meta-analysis. Although we will receive cleaned data,
- 199 we will conduct additional examination of variables quantitatively and visually by checking
- distributions, frequencies, missingness, and outliers (biological or statistical). For instance, for
- the LAZ outcome and all other z-scores, we will use the WHO criteria in determining
- biologically implausible values using the recommended cutoffs (LAZ <-6 or >+6; WAZ <-6 or
- 203 >+5, WLZ, MUAC z-score, and head circumference z-score <-5 or >+5) (22,23). Next, we will
- 204 complete initial transformations to normalize continuous distributions and categorize variables as
- 205 appropriate. This step will include re-coding or creating new variables to align variable
- 206 definitions for analysis with the proposed definitions from the prior harmonization work (13).
- Further, we will query any anomalies and compare the sample sizes and descriptive statistics
- with prior publications and study protocols. We will resolve any data issues or questions with the
- 209 investigators for the corresponding trial. Then, we will be able to combine individual trial data
- sets into an analytic data set along with a variable to indicate which trial the data came from. The
- final product of this stage will be a merged dataset that is ready for the main analysis.

212 Statistical IPD meta-analysis plan

213 Data validation and merging will be conducted in Stata (StataCorp, College Station, Texas); data

- analysis and graphic presentation of the results will be run in Stata and R (R Core Team). To
- investigate the effects of the BEP intervention package on outcomes, a one-stage IPD approach
- will be implemented for all analyses (24). This approach is preferred over the conventional two-
- stage IPD approach, in which trial-level aggregated summary data are pooled in the first stage for
- a meta-analysis model in the second stage (25,26). Overall, the use of a one-stage IPD approach
- will allow us to adopt more appropriate likelihood functions, make fewer model assumptions,and incorporate more effective modelling of effect modifiers to accommodate the between-study
- heterogeneity while we quantify the effects of BEP on maternal and child outcomes (27).
- 222
- For the main analysis, the BEP intervention package will include all study arms that provided
- BEP to women (in the MumtaLW trial, BEP and BEP with infant azithromycin are combined;
- for the other trials, there is only one BEP arm). For continuous outcomes measured at six months
- of infant age, the effect of BEP on the outcome (e.g., LAZ) will be assessed with mixed-effects
- 227 linear regression models. For dichotomous outcomes (e.g., stunting), the effect of BEP on the
- outcome will be assessed using relative risk estimates from mixed-effects log binomial models
- 229 (or alternatively, Poisson regression if log-binomial models do not converge). We will perform
- both univariable analysis (BEP intervention and trial in model) and multivariable analysis
- 231 (adding adjustment for baseline individual- and study-level characteristics) to examine the effect
- of BEP on outcomes. For multivariable models, we will include variables that are statistically
- significant predictors of the same outcome in the univariable analysis and variables that are
- unbalanced at baseline in randomized groups. In all models, intervention arm will be specified as
- a fixed effect, trial will be specified as a random effect (to account for heterogeneity between
- trials), and any other variables in multivariable models will be specified as fixed effects.
- Heterogeneity between trials will be assessed using I^2 statistics. Risk of bias assessments will be
- carried out and reported for each of the individual trials using the Cochrane risk of bias tool.

239 Subgroup Analysis: individual-level and study-level effect modification

- 240 We plan to examine effect modifiers because understanding which groups may benefit the most
- from BEP supplementation is an important goal of this initiative. An interaction term between
- the treatment and a potential effect modifier will be included in separate mixed-effects linear or
- log binomial (or Poisson) regression models. We will examine the following individual-level
- subgroups based on biological plausibility and prior literature: maternal age (<20 y, 20-29 y, \geq 30
- 245 y), education (none vs ≥ 1 year), parity (1 child vs ≥ 2 children), maternal BMI (<18.5 kg/m² vs
- $\geq 18.5 \text{ kg/m}^2$), maternal height (<150 cm vs $\geq 150 \text{ cm}$), MUAC (<23 cm vs $\geq 23 \text{ cm}$)(28), infant
- sex (male vs female), and infant malnutrition as defined by low birth weight (<2,500 g vs \geq
- 248 2,500 g), stunting (LAZ <-2 vs \geq -2), wasting (WLZ <-2 vs \geq -2), and underweight (WAZ <-2 vs
- 249 \geq -2). Study-level variables we plan to examine are: prevalence of infant stunting at baseline, and
- 250 prevalence of maternal underweight at baseline.
- 251
- In a set of exploratory analyses, we will examine if breastfeeding types (exclusive, predominant,
- 253 partial) mediate the effect of BEP on the outcomes at six months. We will also analyze
- differences in benefits to maternal outcomes by levels of BEP adherence (<80% vs $\ge 80\%$),
- which can be useful in planning future studies or dissemination efforts.

256 Significance level

257 We will set an alpha cutoff of p < 0.05 to determine if our results are significantly different from

- those expected if the null hypothesis was correct. For testing interactions, we will use a cutoff of
- p <0.10. The method of Benjamini and Hochberg (29) will be applied to control for false
- discovery in multiple comparisons in the assessment of interaction effects in subgroup analyses.
- 261

262 Missing data

- 263 The IPD meta-analysis will be analyzed based on an intent-to-treat protocol, which assumes that
- all randomized individuals will be included in the analyses. However, if we observe more than
- 265 20% of data missing per treatment arm, it will be flagged as potential bias (differential
- missingness), and we will consider two possible approaches, either performing multiple
- imputation assuming that data are missing-at-random (30,31), or modeling the missing data by
- building a Bayesian hierarchical modeling and test different missing data patterns (32). The
- robustness of the results will be tested in sensitivity analyses using complete cases. To estimate
- the missing values, the participant baseline characteristics (maternal age, maternal education,
- 271 maternal BMI and height at baseline, parity, household food insecurity, baseline value of LAZ,
- and infant sex) will be summarized using descriptive statistics.

273 Sensitivity analysis

- 274 We will test a two-stage approach in sensitivity analyses to assess the robustness of our results to
- different approaches. Usually, both approaches provide similar results (25,26). We will also
- assess the effects of variations in interventions such as BEP alone vs BEP with azithromycin vs
- 277 control; BEP given with vs. without an IFA tablet; and differences in nutrient content (e.g., total
- calories (400 vs 600 vs 800 kcals)) in BEP products.

279 Ethics and dissemination

- For each individual trial, local ethical approval was obtained. This IPD meta-analysis uses de-
- identified data (deemed exempt from ethical approval). A centralized data repository will
- provide the pooled and de-identified datasets for data analysis. Further, the results of this work
- will seek peer-review and publication in fully open-access journals.

284 **DISCUSSION**

- Since 2016, the WHO has recommended BEP supplementation for pregnant women in settings
- with high rates of undernourishment to reduce incidence of small for gestational age and
- stillbirth. However, there are no current BEP recommendations for lactating women, and similar
- to pregnancy, more energy and nutrients are required in this life stage. In response, this
- prospective IPD meta-analysis aims to fill in that gap and investigate the effects of BEP
- supplementation given to lactating women. We will assess infant and maternal outcomes and
- identify subgroups that may benefit the most from this intervention. Prior systematic reviews and
- meta-analysis studies have suggested that BEP supplementation given to pregnant women may
- improve low birth weight, birth weight, small for gestational age, and stillbirth outcomes (8–12);
- improvements to maternal and child health from BEP in lactation are expected.
- 295
- 296 The four BEP trials included in our meta-analysis are conducted in low- and middle-income
- countries among women at risk of or with undernutrition. The BEP intervention is administered
- either in the form of a packaged supplement or snack, with all studies providing $\leq 25\%$ of energy
- from protein. Unlike prior BEP research, the proposed IPD meta-analysis study has harmonized

definitions for key variables of interest, and we will use concurrently conducted RCTs, whichshould improve the quality of data and the reliability of our estimates.

302

This study protocol has several strengths. Generally speaking, prospectively planned IPD metaanalysis is superior to retrospective IPD meta-analysis or aggregate meta-analysis because it is

the least biased and most reliable in producing quality results. Additionally, this approach allows

the combination of study- and individual-level variables from multiple trials into one dataset,

thereby improving the power to assess overall effect estimates and effect modifiers. The effect

modifiers can identify which groups of lactating women benefit the most from BEP
 supplementation (if any). We will also be able to include study-specific random effects into the

analyses and investigate the influence of covariates on heterogeneity of treatment effects. These

aspects will strengthen the current but limited evidence on BEP interventions and help generalize

- 312 the findings in food insecure settings.
- 313

This study has a few limitations that should be considered when interpreting results. Although all

studies provided BEP to lactating women, there are variations in the form and quantity of the

BEP. For instance, in the IMPRINT and MumtaLW trials, BEP provides 600 and 800 kcals,

respectively, which is a higher amount than the recommended range of 250-500 kcals (7).

Further, the control group varies, which may impact our results. For example, IFA is not the

standard of care in lactation in all settings, such as in Nepal. Also, compliance is not measured in all trials for the control group, especially when this group is advised to take advantage of the

national standard of care available. Furthermore, the included trials have some differences in

study design, data definitions, and data collection methods. Substantial efforts were made later to

harmonize the primary and secondary outcome measures, in our case, through the BEP Initiative

324 (13). Last, studies also differ in eligibility criteria, and one study only enrolled women that were

undernourished. However, we will test in subgroup analyses if maternal undernourishment status

- is an important factor in the BEP treatment effect.
- 327

328 Ultimately, this prospective IPD meta-analysis protocol will extend our knowledge on the

effectiveness of giving BEP supplementation to lactating women on infant growth and other

important maternal and infant outcomes. Thus, this work aims to overcome prior challenges and

clarify the benefits of BEP in dyads from low-and middle-income settings. The results of this

study will be disseminated through publication in fully open-access peer-reviewed journals.

- 333 Trial status
- Protocol version 2. The project began on October 15, 2020. It is funded by the Bill & Melinda
- Gates Foundation until April 14, 2024. We preregistered the lactation meta-analysis on Open
- 336 Science Framework (https://osf.io/9nq7z) on October 4, 2022. This protocol manuscript mirrors
- our preregistration but expands and adds important details for the included trials and data
- analysis methods. We have received data from three out of four participating trials via an
- external data repository. The data collection is on-going for the fourth trial and will conclude in
- the first quarter of 2024, when we anticipate to have the complete pooled dataset.
- 341
- 342 List of abbreviations
- 343 AGP alpha-1-acid glycoprotein
- 344 BEP balanced energy-protein
- 345 BMGF Bill & Melinda Gates Foundation
- 346 BMI Body Mass Index
- 347 CRP C-reactive protein
- 348 IFA iron and folic acid
- 349 IPD individual participant data
- 350 LAZ length-for-age *z*-score
- 351 LMIC low and middle-income countries
- 352 MUAC mid-upper arm circumference
- 353 RCT randomized controlled trial
- 354 WAZ weight-for-age *z*-score
- 355 WHO World Health Organization
- 356 WLZ weight-for-length *z*-score

357 **DECLARATIONS**

- 358 Ethics approval and consent to participate
- For each individual trial, local ethical approval was obtained. This IPD meta-analysis will use
- 360 de-identified data (deemed exempt from ethical approval by the Institutional Review Board at
- Penn State). The de-identified and harmonized IPD meta-analysis dataset will be stored in a data
- repository. The research findings will be disseminated in peer-reviewed, open-access journals.
- 363 Consent for publication
- 364 Not applicable
- 365 Availability of data and materials
- No data available at this stage
- 367 Competing interests
- All authors have been funded by the Bill & Melinda Gates Foundation. Parul Christian worked at
- the BMGF from 2015-2019 during which the BEP trials were funded. All other authors, co-
- authors, and collaborators have nothing to declare. JT participated on a Data Safety Monitoring
- Board or Advisory Board at University of North Carolina and University of California San
- Francisco on studies unrelated to this manuscript. JT was a non-profit board member, unpaid, for
- the Helen Keller International, which may use the results of these trials, depending on the results,

- in their programming. JT was a non-profit board member, unpaid, for the Health Volunteers
- 375 Overseas that conducts work unrelated to the topic of this manuscript.

376 Funding source \Box

- This work was funded by the Bill & Melinda Gates Foundation, investment grant number INV-
- 022373. The funder had no role in the study design, collection, analysis, and interpretation of
- 379 data and in writing the manuscript.
- 380 Authors' contributors
- MAC and SZ drafted the study protocol with critical guidance and input from ADG and KG. NB,
- 382 PK, AM, ST, JT, RC, PC, AA, TD-C, BK, DE, FJ, JK, SK, CL, TL, MN, YS, RU contributed to
- the original data acquisition and to the BEP Initiative, providing input and feedback to the meta-
- analysis plans throughout the process. ADG led overall study design and BEP Initiative work
- with input from all authors. All authors read, commented, and approved the final protocol. This
- protocol is written on behalf of the Maternal BEP Studies Harmonization Initiative.
- 387
- 388 Acknowledgements We would like to thank all members of each research team for the studies
- included in the BEP Initiative. Our Technical Advisory Group, Drs. Martha Mwangome, Wafaie
- 390 Fawzi, Sant-Rayn Pasricha, Parul Christian, and Rajiv Bahl served as scientific advisors, and we
- 391 are grateful for their important guidance. Collaborators listed under **Maternal BEP Studies**
- **Harmonization Initiative:** Eleonor Zavala, Steven C. LeClerq (Johns Hopkins Bloomberg
- 393 School of Public Health), Benazir Baloch (Aga Khan University),
- Lieven Huybregts (International Food Policy Research Institute), Laeticia C Toe (Institut de
- Recherche en Sciences de la Santé Burkina Faso), Giles Hanley-Cook (Ghent University), Grace
- J Chan (Boston Children's Hospital), Mulatu M Derebe (Amhara Public Health Institute), Fred
- van Dyk, Luke C Mullany, Daniel Erchick (Johns Hopkins Bloomberg School of Public Health),
- 398 Michelle S Eglovitch, Chunling Lu, Krysten North, Ingrid E Olson (Brigham and Women's
- Hospital), Nebiyou Fasil, Workagenehu T Kidane, Fisseha Shiferie, Tigest Shifraw, Fitsum
- 400 Tsegaye, Sitota Tsegaye (Addis Continental Institute of Public Health), Sheila Isanaka (Harvard
- 401 TH Chan School of Public Health), Rose Molina, Michele Stojanov, Blair Wylie, (Beth Israel
- 402 Deaconess Medical Center), Amare W Tadesse (London School of Hygiene and Tropical
- 403 Medicine and Addis Continental Institute of Public Health)

References

- Kozuki N, Katz J, Lee ACC, Vogel JP, Silveira MF, Sania A, et al. Short Maternal Stature Increases Risk of Small-for-Gestational-Age and Preterm Births in Low- and Middle-Income Countries: Individual Participant Data Meta-Analysis and Population Attributable Fraction. J Nutr. 2015 Nov;145(11):2542–50.
- 2. World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience [Internet]. 2016 [cited 2022 Feb 2]. Available from: https://www.who.int/publications-detail-redirect/9789241549912
- 3. Nommsen LA, Lovelady CA, Heinig MJ, Lönnerdal B, Dewey KG. Determinants of energy, protein, lipid, and lactose concentrations in human milk during the first 12 mo of lactation: the DARLING Study. Am J Clin Nutr. 1991 Feb;53(2):457–65.
- 4. World Health Organization. Joint child malnutrition estimates-levels and trends (2019 edition). WHO Geneva Httpswww Who Intnutgrowthdbestimates2017en. 2018;
- 5. Local Burden of Disease Child Growth Failure Collaborators. Mapping child growth failure across low-and middle-income countries. Nature. 2020;577(7789):231–4.
- UNICEF/WHO/World Bank Group. Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates: key findings of the 2023 edition [Internet]. 2023 [cited 2023 May 26] p. 32. Available from: https://www.who.int/publications-detail-redirect/9789240073791
- 7. Report of an Expert Consultation held at the Bill & Melinda Gates Foundation. Framework and specifications for the nutritional composition of a food supplement for pregnant and lactating women (PLW) in undernourished and low income settings. Gates Open Res. 2017;3(1498):1498.
- 8. Imdad A, Bhutta ZA. Maternal nutrition and birth outcomes: effect of balanced proteinenergy supplementation. Paediatr Perinat Epidemiol. 2012 Jul;26 Suppl 1:178–90.
- Ota E, Hori H, Mori R, Tobe □ Gai R, Farrar D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database Syst Rev [Internet]. 2015 [cited 2022 Feb 2];(6). Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000032.pub3/full
- 10. Stevens B, Buettner P, Watt K, Clough A, Brimblecombe J, Judd J. The effect of balanced protein energy supplementation in undernourished pregnant women and child physical growth in low- and middle-income countries: a systematic review and meta-analysis. Matern Child Nutr. 2015;11(4):415–32.
- 11. Lassi ZS, Padhani ZA, Rabbani A, Rind F, Salam RA, Bhutta ZA. Effects of nutritional interventions during pregnancy on birth, child health and development outcomes: A systematic review of evidence from low- and middle-income countries. Campbell Syst Rev. 2021;17(2).

- 12. Perumal N, Blakstad MM, Fink G, Lambiris M, Bliznashka L, Danaei G, et al. Impact of scaling up prenatal nutrition interventions on human capital outcomes in low- and middle-income countries: a modeling analysis. Am J Clin Nutr. 2021 Nov 8;114(5):1708–18.
- Gernand AD, Gallagher K, Bhandari N, Kolsteren P, Lee AC, Shafiq Y, et al. Harmonization of maternal balanced energy-protein supplementation studies for individual participant data (IPD) meta-analyses – finding and creating similarities in variables and data collection. BMC Pregnancy Childbirth. 2023 Feb 11;23(1):107.
- 14. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Dec;4(1):1–9.
- 15. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement. JAMA. 2015 Apr 28;313(16):1657–65.
- 16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:14898.
- 17. Becquey E, Huybregts L, Zongrone A, Le Port A, Leroy JL, Rawat R, et al. Impact on child acute malnutrition of integrating a preventive nutrition package into facility-based screening for acute malnutrition during well-baby consultation: A cluster-randomized controlled trial in Burkina Faso. PLoS Med. 2019 Aug;16(8):e1002877.
- 18. Taneja S, Upadhyay RP, Chowdhury R, Kurpad AV, Bhardwaj H, Kumar T, et al. Impact of nutritional interventions among lactating mothers on the growth of their infants in the first 6 months of life: a randomized controlled trial in Delhi, India. Am J Clin Nutr. 2021 Apr 6;113(4):884–94.
- 19. Muhammad A, Shafiq Y, Nisar MI, Baloch B, Yazdani AT, Yazdani N, et al. Nutritional support for lactating women with or without azithromycin for infants compared to breastfeeding counseling alone in improving the 6-month growth outcomes among infants of peri-urban slums in Karachi, Pakistan—the protocol for a multiarm assessor-blinded randomized controlled trial (Mumta LW trial). Trials. 2020 Sep 1;21(1):756.
- 20. Vanslambrouck K, Kok B de, Toe LC, Cock ND, Ouedraogo M, Dailey-Chwalibóg T, et al. Effect of balanced energy-protein supplementation during pregnancy and lactation on birth outcomes and infant growth in rural Burkina Faso: study protocol for a randomised controlled trial. BMJ Open. 2021 Mar 1;11(3):e038393.
- 21. World Health Organization. 2018 Global reference list of 100 core health indicators (plus health-related SDGs). Geneva; 2018.
- 22. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Oslo Nor 1992 Suppl. 2006 Apr;450:76–85.

- 23. World Health Organization. WHO Anthro Survey Analyser; Quick guide. 2019; Available from: https://cdn.who.int/media/docs/default-source/child-growth/child-growth-standards/software/anthro-survey-analyser-quickguide.pdf?sfvrsn=dc7ddc6f_6
- 24. Riley RD, Legha A, Jackson D, Morris TP, Ensor J, Snell KIE, et al. One-stage individual participant data meta-analysis models for continuous and binary outcomes: Comparison of treatment coding options and estimation methods. Stat Med. 2020;39(19):2536–55.
- 25. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010 Feb 5;340:c221.
- 26. Debray TPA, Moons KGM, Abo-Zaid GMA, Koffijberg H, Riley RD. Individual Participant Data Meta-Analysis for a Binary Outcome: One-Stage or Two-Stage? PLOS ONE. 2013 Apr 9;8(4):e60650.
- 27. Kontopantelis E. A comparison of one-stage vs two-stage individual patient data metaanalysis methods: A simulation study. Res Synth Methods. 2018 Sep;9(3):417–30.
- 28. Ververs M tesse, Antierens A, Sackl A, Staderini N, Captier V. Which Anthropometric Indicators Identify a Pregnant Woman as Acutely Malnourished and Predict Adverse Birth Outcomes in the Humanitarian Context? PLoS Curr [Internet]. [cited 2023 Jul 17];5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682760/
- 29. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.
- 30. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–99.
- 31. Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol. 2014 Nov 19;14(1):118.
- 32. Hong H, Chu H, Zhang J, Carlin BP. A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons. Res Synth Methods. 2016;7(1):6–22.

Full study name	Short name	Country	Study design ¹	Sample size	Enrollment dates	Registry	References
Nutritional Interventions to Improve Linear Growth during Infancy in India: Supplementing Lactating Mothers	IMPRINT	India	Individual randomization Arm 1: BEP Arm 2: Control	816	April 2018 – January 2020	Clinical Trials Registry-India CTRI/2018/04/0130 95	Taneja et al. 2021
Mumta Lactating Women Trial	MumtaLW	Pakistan	Individual randomization Arm 1: BEP Arm 2: BEP with Azithromycin (infants only) Arm 3: Control	957 ³	June 2018 – January 2021	ClinicalTrials.gov NCT03564652	Muhammad et al. 2020
MIcronutriments pour la SAnté de la Mère et de l'Enfant-III ²	MISAME- III	Burkina Faso	Individual randomization with factorial design ³ Arm 1: BEP Arm 2: Control	800 ⁴	October 2019 – December 2020	ClinicalTrials.gov NCT03533712	Vanslambrouck, Kok, et al. 2021
Maternal Infant Nutrition Trial	MINT	Nepal	Household randomization with factorial design ³ Arm 1: BEP Arm 2: Control	726 ⁴	November 2021 – June 2022 (second cohort: January 2023- July 2023) ⁵	ClinicalTrials.gov NCT03668977	

Table 1: Study information for the maternal BEP lactation trials that will be included in the IPD meta-analysis

¹Intervention and control given for 6 months postpartum; all trials provided multiple micronutrients as part of BEP intervention; MumtaLW and MISAME-III gave iron-folic acid supplements to both intervention and control for 6 weeks; see Table 2 for details

²French to English translation: Micronutrients for the health of the mother and infant

³Factorial design for MISAME-III and MINT was random assignment for pregnancy and random assignment for postpartum. Only data on

lactation will be used for this portion of the meta-analysis

⁴Sample size for enrollment (final analytic sample size may be different) ⁵The MINT trial had a break in enrollment

	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		<b>BEP</b> interv	vention give	en during the la	ctation period	
Study	Serving size (g)	Kcals	Protein (g)	Fat (g)	Description	Micronutrients	Control given during the lactation period
IMPRINT	140-150	600	20	15-20	5 different locally prepared snacks (Hungry Foal Company)	MMN tablet provided containing: vitamins A, C, D, E, B6, and B12, folate, thiamin, riboflavin, niacin, copper, iron, iodine, zinc, and selenium Encouraged to use IFA, calcium, and vitamin D for 6 months available through national program (supplement that provides 600 kcals [18-20 g protein] also available but has low coverage)	Encouraged to use IFA, calcium, and vitamin D for 6 months available through national program (supplement that provides 600 kcals [18-20 g protein] also available but has low coverage)
MumtaLW	150 ²	800	21	24	BEP product (Ismail Industries, certified by World Food Program)	<ul> <li>BEP was fortified with MMN: vitamins A, C, E,</li> <li>B1, B2, B6, B12, folic acid, niacin, pantothenic acid, calcium, copper, iodine, iron, magnesium, manganese, selenium, zinc, phosphorus, potassium</li> <li>IFA tablet given for 6 weeks (by government program, or by trial if participant did not receive</li> </ul>	IFA tablet given for 6 months (by government program, or by trial if participant did not receive from program)

**Table 2**: BEP and control trial arm descriptions of energy and nutrients provided to women in the lactation trials that will be included in the IPD meta-analysis¹

# from program)

MISAME- III	72	393	14.5	26	BEP product (Nutriset Company)	BEP was fortified with MMN: vitamins A, C, D, E, B1, B2, B6, and B12, folic acid, niacin, K, calcium, copper, iron, iodine, phosphorus, selenium, and zinc	IFA tablet given for 6 weeks (by trial)
MINT	72	391	14.7	26	BEP product (Nutriset Company)	IFA tablet provided for 6 weeks (by trial) BEP was fortified with MMN: vitamins A, C, D, E, B1, B2, B6, and B12, folic acid, niacin, K, calcium, copper, iron, iodine, phosphorus, selenium, and zinc	No IFA from trial or government program (not part of standard of care during lactation)

¹Groups in the intervention and control received the standard of care for maternal and infant clinical care. Trials also provided healthbased counseling (e.g., on breastfeeding), which varied by study. Further details can be found in each trial's published protocol. ²Values for serving size, kcals, and protein represent two sachets of BEP (75 g each).

Abbreviations: BEP=Balanced energy-protein; IFA=Iron and folic acid; IMPRINT=Nutritional Interventions to Improve Linear Growth during Infancy in India: Supplementing Lactating Mothers; MISAME-III=MIcronutriments pour la SAnté de la Mère et de l'Enfant-III or Micronutrients for the health of the mother and infant; MMN=Multiple micronutrients; MumtaLW=Mumta Lactating Women Trial

Study	of BEF factation trais	Infant or	Measurements/
outcomes	Variables	Maternal	Units
Primary	Length-for-age z-score (LAZ)	Infant	z-score
Secondary	Weight-for-length z-score (WLZ)	Infant	z-score
	Weight-for-age z-score (WAZ)	Infant	z-score
	Growth velocity (birth to 6 months)	Infant	g/kg/day
	Stunting	Infant	LAZ <-2; %
	Wasting	Infant	WLZ <-2; %
	Underweight	Infant	WAZ <-2, %
	Body mass index (BMI)	Maternal	kg/m ²
	Mid-upper arm circumference (MUAC)	Maternal	cm
	Low MUAC	Maternal	MUAC <23.0 cm
	Underweight	Maternal	BMI <18.5 kg/m ²
Exploratory	Head circumference-for-age z-score	Infant	z-score
	MUAC-for-age z-score	Infant	z-score
	Ferritin	Infant & maternal	ng/mL
	Transferrin receptor	Infant & maternal	mcg/dL
	Hemoglobin	Infant & maternal	g/dL
	C-reactive protein (CRP)	Infant & maternal	mg/L
	Alpha-1-acid glycoprotein (AGP)	Infant & maternal	mg/dL
	Iron deficiency	Infant & maternal	%
	Anemia	Infant & maternal	%
	Infant mortality rate (birth to 6 months)	Infant	per 1,000 live births
	Maternal mortality rate (birth to 6 months)	Maternal	per 100,000 live births

**Table 3**: Maternal and infant outcomes (at six months of infant age) to be assessed in the IPD meta-analysis of BEP lactation trials

Indices were assessed based on World Health Organization Growth Standards(21) and INTERGROWTH-21st methodology. Abbreviations: BEP=Balanced Energy-Protein supplementation; IPD=Individual Participant Data